540PClinical outcomes in non–small cell lung cancer patients with ultra-high expression of programmed death ligand-1 treated with pembrolizumab as first-line therapy: A retrospective multicenter cohort study. (25th November 2018) - Kurebe, H; Edahiro, R; Kanazu, M; Fujimoto, D; Tamiya, M; Tamiya, A; Suzuki, H; Hirano, K; Yokoyama, T; Morita, M; Fukuda, Y; Uchida, J; et al.